Trial Profile

A NIS of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer in Argentina and Brazil -LATAM AVENUE

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary)
Indications Urogenital cancer
Focus Therapeutic Use
Acronyms LATAM AVENUE
Sponsors Pfizer

Most Recent Events

11 Jul 2023 Status changed from recruiting to discontinued. The trial terminated due to the inability to recruit the planned number of subjects. Thedecision was not based on any safety and/or efficacy concerns.
08 Mar 2023 Status changed from not yet recruiting to recruiting.
21 Nov 2022 Planned primary completion date changed from 30 Nov 2022 to 15 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com